ClinicalTrials.gg
CompletedNCT06501534Updated Mar 27, 2025

A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

A Phase 2 interventional study of Febuxostat and IBI128 in Gout and Hyperuricemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.

Enrollment
24th of 44
84 · median 93
Started
2024
with 4 others
Phase 2
4 of 49
none open now
Registered
34th of 49
by date
Lead sponsor
2 of 49
Innovent Biologics (Suzhou) Co. Ltd.

Among the 49 studies in Gout with a site in China, this one is the 24th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2024, is one of 4 in phase 2, and was the 34th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Gout with a site in China, or all of them as a file.
02

Study summary

IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid.

This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be aged between 18 and 75 years old (inclusive, as of the time of signing the form), with no gender restrictions;
  2. (BMI) should fall within the range of 18.0 to 40.0 kg/m² (including both ends of the range);
  3. Subjects must meet the 2015 ACR/EULAR classification criteria for the diagnosis of gout (refer to Appendix 4);
  4. At the screening stage, subjects must have a blood uric acid level of ≥480 μmol/L;
  5. Subjects must voluntarily sign the informed consent form and agree to strictly adhere to the requirements outlined in this protocol.

Exclusion criteria

Exclusion criteria (brief):

  1. History of allergy to any component of Tigulixostat;
  2. Previous allergy or intolerance to Febuxostat;
  3. Subjects who have taken uric acid lowering medications within 2 weeks prior to screening;
  4. Subjects who experienced an acute gout flare-up within 4 weeks prior to screening or immediately before the first dose administration;
  5. Subjects considered to have secondary gout (elevated serum uric acid due to causes other than renal insufficiency);
  6. Subjects with a history of xanthinuria.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    Febuxostat 40mg

    Tablets, Once a day (QD), Per oral

    Drug: Febuxostat

  • Experimental
    IBI128 50mg

    Tablets, Once a day (QD), Per oral

    Drug: IBI128

  • Experimental
    IBI128 200mg

    Tablets, Once a day (QD), Per oral

    Drug: IBI128

  • Experimental
    IBI128 100mg

    Tablets, Once a day (QD), Per oral

    Drug: IBI128

Interventions

  • Tablets, Once a day (QD), Per oral

  • DrugIBI128

    Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral

06

What researchers measure

Primary outcomes

  1. The proportion of subjects in each treatment group with serum uric acid levels <360 μmol/L after continuous treatment for 16 weeks

    Time frame: Week 16

Secondary outcomes

  1. The proportion of subjects in each treatment group with serum uric acid levels <300 μmol/L after continuous treatment for 16 weeks

    Time frame: Week 16

  2. The proportion of subjects in each treatment group with serum uric acid levels <360, <300 μmol/L after continuous treatment for 2, 4, 8, 12 weeks

    Time frame: Week 2, 4, 8, 12

  3. Absolute and percentage Changes in serum uric acid levels from baseline in subjects of each treatment group after continuous treatment for 2, 4, 8, 12, and 16 weeks

    Time frame: Baseline, Week 2, 4, 8, 12

  4. The proportion of subjects experiencing gout flares and the number of gout flare occurrences within every 4 weeks from the first dose, among those receiving various doses of Tigulixostat tablets and Febuxostat tablets

    Time frame: Baseline through Week 16/18

  5. Number of subjects with Adverse Event, Serious Adverse Events, Treatment Emergent Adverse Event, Adverse event of special interest

    Time frame: Baseline through Week 18/20

  6. Number of subjects with clinically significant changes in physical examination results

    Clinically significant abnormal physical examination findings reported by the investigator.

    Time frame: Baseline through Week 16/18

  7. Number of subjects with clinically significant changes in in vital sign

    Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure.

    Time frame: Baseline through Week 16/18

  8. Number of subjects with clinically significant changes in clinical laboratory parameters

    Clinical laboratory parameters including white blood cell, red blood cell, hemoglobin, platelet, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum creatinine, fasting serum glucose, toal bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, serum potassium, creatine phosphokinase, hs-CRP, prothrombin time, thrombin time, activated partial thromboplastin time, international normalized ratio

    Time frame: Baseline through Week 16/18

  9. Number of subjects with clinically significant changes in electrodiagram

    Electrodiagram parameters including PRinterval, heart rate, RRinterval, corrected QT interval by Fridericia's formula

    Time frame: Baseline through Week 16/18

  10. Plasma concentration of Tigulixostat

    Time frame: Baseline through Week 16/18

07

Study locations

1 site
  • Shanghai Fudan University HuaShan Hospital
    Shanghai, Shanghai 200040, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Dec 2024, 5 months.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 15, 2024
StartActual
Jul 10, 2024
Primary completionActual
Dec 13, 2024
CompletionActual
Jan 9, 2025
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501534
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jul 10, 2024
Primary completion
Dec 13, 2024
Completion
Jan 9, 2025
Last update
Mar 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion